// App-Quantinova.ai

524 : Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17.

Researchers

Presenter

  • Pedro Emanuel Rubini Liedke

Principal Investigators

  • Yanin Chavarri-Guerra

  • Lois E. Shepherd

  • Dongsheng Tu

  • Kathleen I. Pritchard

  • Paul Edward Goss

Medical Centers

  • Massachusetts General Hospital, Avon International Breast Cancer Center, Boston, MA

  • NCIC Clinical Trials Group, Kingston, ON, Canada

  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory Arthritis

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Letrozole

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved